All Drug Discovery Processes articles
-
ArticleAI to antibody in days: breaking the wet lab bottleneck via high-throughput integration
AI is accelerating drug discovery at an unprecedented pace. Thousands of antibody candidates can now be designed in silico within hours. The challenge now is keeping experimental workflows fast enough to keep up. High-throughput expression and integrated developability assessment are making it possible to move from sequence to data in days.
-
ArticleOperational data: the hidden driver of faster drug discovery
The key to faster, smarter drug discovery lies in data that’s often overlooked. By exposing hidden delays and inefficiencies, this data enables teams to shorten discovery cycles and progress promising candidates faster.
-
NewsMirrored molecules target disordered proteins in Alzheimer’s disease
Researchers at Kobe University have developed a novel approach to Alzheimer’s disease treatment by engineering right-handed amino acid chains that bind to amyloid-beta proteins. The method, inspired by materials science principles of chirality, demonstrated effective inhibition of toxic protein aggregation in mouse brain cell cultures, maintaining cell viability where amyloid-beta alone reduced it by 50 percent.
-
NewsScientists scale up neural organoid studies for drug testing
Researchers at King’s College London have developed a hybrid neural organoid approach that addresses longstanding limitations in scalability, reproducibility and longitudinal analysis. By dissociating 3D organoids and culturing pooled cells on microelectrode arrays, the team created 2D networks that retain cellular diversity whilst enabling consistent, long-term tracking of neural activity across parallel cultures.
-
NewsScientists link IVNS1ABP gene to new ageing disorder
An international research team has identified a previously unknown genetic disease characterised by premature ageing and progressive neurological decline. Using genome sequencing combined with induced pluripotent stem cell technology, scientists traced the condition to a mutation in the IVNS1ABP gene and uncovered disrupted actin dynamics during cell division as the underlying pathological mechanism.
-
NewsAI discovers peptide that eases ulcerative colitis symptoms
Researchers at First Hospital of Jilin University have used machine learning to identify antimicrobial peptides with therapeutic potential for ulcerative colitis. The AI-driven approach screened over 6,000 candidates, identifying a lead peptide that demonstrated superior efficacy to standard treatments in preclinical models by reducing inflammation, restoring gut barrier integrity and selectively modulating the microbiome.
-
NewsBlocking protein pathway may slow Huntington’s disease
Researchers have identified a previously unknown cellular mechanism involving tunnelling nanotubes and the protein SLC4A7 that enables toxic huntingtin to spread directly between neurons, offering new therapeutic targets for Huntington’s disease.